Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Biogen Idec Stories

2014-04-17 12:30:37

DUBLIN, April 17, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fclw7g/global_hemophilia) has announced the addition of the "Global Hemophilia Market 2014-2018" [http://www.researchandmarkets.com/research/fclw7g/global_hemophilia ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Hemophilia market to grow at a CAGR of 6.07 percent over the period...

2014-04-15 12:30:41

Market Access Challenges for Sanofi/Genzyme's Aubagio Highlight the Hurdles New Multiple Sclerosis Agents Face in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., April 15, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed neurologists in France, Germany, Italy, Spain, and the United Kingdom (EU5) project that 16 percent of their diagnosed relapsing-remitting multiple sclerosis (MS) patients on average will receive Biogen Idec's Tecfidera within...

2014-04-15 08:28:24

DUBLIN, Apr. 15, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6zn3pr/global_microrna ) has announced the addition of the "Global MicroRNA Market Report" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The analysts forecast the Global MicroRNA market to grow at a CAGR of 17.51 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in microRNA research funding....

2014-04-11 16:21:36

DUBLIN, April 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/btp9ds/global_multiple) has announced the addition of the "Global Multiple Sclerosis (MS) Therapeutics Market Report" [http://www.researchandmarkets.com/research/btp9ds/global_multiple ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Multiple Sclerosis (MS) Therapeutics market to grow at...

2014-04-09 08:28:17

TEL AVIV, Israel, April 9, 2014 /PRNewswire/ -- Medison Pharma has concluded an agreement with the medical device company Brainsway for exclusive marketing and distribution of the Deep TMS (Transcranial Magnetic Stimulation) system in Israel. Medison Pharma will be Brainsway's exclusive agent for a period of 10 years with a 5 year extension option for the system's treatment of the following indications approved by the Israeli Ministry of Health: Major depression, Bipolar...

2014-04-09 08:26:02

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 9, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Actavis Plc (NYSE: ACT), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at:...

2014-04-08 23:21:41

Comprehensive cloud-based Clinical Trial Optimization System transforms clinical operations quality and efficiency from startup through closeout with a single unified platform. Newton, MA (PRWEB) April 08, 2014 TrialNetworks and its Clinical Trial Optimization System won the Disruptive Innovator and Technology of the Year award from Partnerships in Clinical Trials 2014. The award was announced on the final day of the premier industry conference held in Las Vegas, NV. The award honors an...

2014-04-01 08:29:43

Raleigh Convention Center on April 8th RALEIGH, N.C., April 1, 2014 /PRNewswire/ -- An expected 1000 life science professionals from Pfizer, Biogen Idec, Novartis, GlaxoSmithKline, Novo Nordisk, Grifols, and many others will gather at the ISPE-CaSA Life Sciences Technology Conference, Tuesday, April 8, 2014, 10:00 am-7:00 pm (http://ispe-casa.org/2014/) on the top floor of the Raleigh Convention Center, 500 S. Salisbury St., Raleigh, NC, to learn the latest manufacturing techniques through...

2014-03-31 20:22:33

DUBLIN, April 1, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5q5tcr/global_orphan) has announced the addition of the "Concise Analysis of the International Orphan Drug Market Outlook 2018" [http://www.researchandmarkets.com/research/5q5tcr/global_orphan ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global pharmaceutical industry has been experiencing a slow growth in recent...

2014-03-27 12:30:38

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rwdz5w/therapy_class ) has announced the addition of the "Therapy Class Overview: Rituximab biosimilar" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade,...